Efficiently scaled-up production of recombinant human elastin-like polypeptides using multiple optimization strategies.

Elastin-like polypeptides (ELPs) are biopolymers with repetitive amino acid sequences and are known for their biocompatibility and inverse transition cycling (ITC) properties; thus, they are ideal for biomedical applications. Owing to their low yield and tedious purification process with multiple rounds of ITC, no acceptable scaled-up production process has been developed. Here, for the first time, an efficient, low-cost process for the preparation of recombinant human elastin-like polypeptide (rhELP) is reported.

Double promoter and tandem gene strategy for efficiently expressing recombinant FGF21.

Background: Fibroblast growth factor 21 (FGF21) is a promising candidate for treating metabolic disorder diseases and has been used in phase II clinical trials. Currently, metabolic diseases are prevalent worldwide, underscoring the significant market potential of FGF21. Therefore, the production of FGF21 must be effectively improved to meet market demand.